Disproportional response: a small company's current business is visibly outgrowing its own size
The model's full reasoning — Q4 2016 call → NOWe need to determine if management conveys that the business is currently arriving at a scale disproportionately large relative to the company's small size. Look for statements about current orders, commitments, or activity that are large compared to the company's size. The transcript mentions record orders, large multi-system orders, but does management explicitly say these are large relative to the company's smallness? They mention record backlog, record gross orders, but not necessarily a disproportion. They talk about growth, but not that the current activity is out of proportion to the company's size. They mention a single customer order being largest in history, but that's not necessarily disproportionate to the company's size. They also mention that they are a small company? They don't explicitly say "we are small" and "this is huge relative to us." They do mention that they are achieving record numbers, but that's typical. The question asks if management conveys that the business is visibly outgrowing the company's own current size and setup. They mention that they have a record backlog, record orders, but they don't contrast with their smallness. They do mention that they are a company that has just achieved first positive cash flow, but that's not about scale. They also mention that they are investing in R&D and sales, but not that they are overwhelmed. They mention that they have a large order from NHS, but that's just a big order. They don't say "this is disproportionately large for us." They do say that they expect growth, but that's forward-looking. The question is about current activity. They mention that they have a record quarter, but that's not necessarily a disproportion. They also mention that they are a small player in a large market, but they don't say that the current business is large relative to their size. They do mention that they have a $406 million backlog, but that's not necessarily disproportionate. I think the answer is NO because they don't explicitly convey that the current business is disproportionately large relative to their small size. They just report strong results. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
VNRX · Q1 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management explicitly describing the Heska deal (already signed and with $10M upfront received) as a long-term, multi-year commitment that will generate ongoing kit/component revenue "significantly greater" than the $28M milestones, with "millions of tests" expected each year — all while repeatedly noting the company is "not a big company" and that this is "the beginning of our commercial journey" after 12 years of R&D. They contrast this with their tiny current revenue ($114k) and cash position, framing the new activity as disproportionately large relative to their size.
TMCI · Q2 2022 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES Management explicitly describes the business as outgrowing its current setup in present-tense terms: they are “once again in the process of relocating to a larger headquarters facility” to meet “increased requirements” for training, R&D, warehousing, and infrastructure; the direct sales force has grown 52% to 123 quota-carrying reps and is already trending above the year-end 70% direct mix goal; surgeon penetration has reached 20% of the estimated 10,000 U.S. foot-and-ankle surgeons while procedure penetration is 4.6% of the 450,000 annual U.S.
KOPN · Q4 2023 → YESThe question is: Does management convey that the business the company is doing RIGHT NOW is visibly outgrowing the company's own current size and setup? That current activity, demand, or commitments a...YES The transcript shows management describing current activity (a $55 million backlog, a $20.5 million new order, follow-on orders, and tripled weapon-site volume expected in 2024) as large relative to the company’s still-small size and setup. They explicitly note the backlog is a “record level 10 years,” that they had to extend the holiday shutdown and retool the plant for a “significant increase in production,” and that they are “buying to that level of volume today” while remaining conservative on guidance.